Quipt Home Medical

Canaccord Genuity Acts as Joint Bookrunner for Quipt Home Medical on its C$42 Million Bought Deal

Canaccord Genuity is pleased to announce that on April 25, 2023, its client, Quipt Home Medical Corp. (“Quipt” or “the Company”) (NASDAQ:QIPT; TSXV:QIPT) announced that it had closed its previously announced bought deal public offering (the “Public Offering”) of common shares in the capital of the Company (the “Common Shares”).

In connection with the Public Offering, the Company issued a total of 5,129,000 Common Shares at an issue price of C$7.85 per Common Share (the “Issue Price”) for aggregate gross proceeds of C$40,262,650, which includes 669,000 Common Shares issued pursuant to the exercise of the over-allotment option granted to the underwriters. Concurrent with the closing of the Public Offering, the underwriters also completed a brokered private placement, on a commercially reasonable best efforts basis (the “Private Placement”), of 280,000 Common Shares at the Issue Price, for aggregate gross proceeds of C$2,198,000. As a result of the completion of the Public Offering and Private Placement (the “Offering”), the Company has raised aggregate gross proceeds of C$42,460,650. The Company intends to use the proceeds of the Offering for repayment of debt, potential future acquisitions, working capital and general corporate purposes.

Quipt provides in-home monitoring and disease management services including end-to-end respiratory solutions for patients in the United States healthcare market. It seeks to continue to expand its offerings to include the management of several chronic disease states focusing on patients with heart or pulmonary disease, sleep disorders, reduced mobility, and other chronic health conditions. The primary business objective of the Company is to create shareholder value by offering a broader range of services to patients in need of in-home monitoring and chronic disease management.

The Canaccord Genuity team included Steve Winokur, Genevieve Eccleston, and Matthias Eyford from Investment Banking and Jennifer Pardi and Len Sauer from Equity Capital Markets.